Allarity Therapeutics announced the appointment of Jeremy R. Graff, Ph.D., as President and Chief Development Officer effective September 30, 2024. Dr. Graff brings over 25 years of biotech/pharma industry experience, including a 17-year tenure at Eli Lilly where he led the translational oncology group advancing 31 clinical assets. He will oversee the company's clinical development programs, particularly the advancement of stenoparib, a dual PARP and Tankyrase inhibitor.The company has also strengthened its leadership team with two key appointments: Jose Iglesias, M.D., joins as Consultant Chief Medical Officer, bringing 35 years of global pharmaceutical experience including roles at Celgene and Eli Lilly; and Jesper Høiland, former President of Novo Nordisk's U.S. operations, joins as Strategic Advisor.Under his employment agreement, Dr. Graff will receive an annual base salary of $475,000, RSUs valued at $250,000, up to 45% annual bonus opportunity, and a $75,000 signing bonus. The agreement includes severance provisions of nine months' salary for termination without cause, extending to twelve months in case of change-of-control.

Allarity Therapeutics announced the appointment of Jeremy R. Graff, Ph.D., as President and Chief Development Officer effective September 30, 2024. Dr. Graff brings over 25 years of biotech/pharma industry experience, including a 17-year tenure at Eli Lilly where he led the translational oncology group advancing 31 clinical assets. He will oversee the company's clinical development programs, particularly the advancement of stenoparib, a dual PARP and Tankyrase inhibitor.The company has also strengthened its leadership team with two key appointments: Jose Iglesias, M.D., joins as Consultant Chief Medical Officer, bringing 35 years of global pharmaceutical experience including roles at Celgene and Eli Lilly; and Jesper Høiland, former President of Novo Nordisk's U.S. operations, joins as Strategic Advisor.Under his employment agreement, Dr. Graff will receive an annual base salary of $475,000, RSUs valued at $250,000, up to 45% annual bonus opportunity, and a $75,000 signing bonus. The agreement includes severance provisions of nine months' salary for termination without cause, extending to twelve months in case of change-of-control.